The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.
Zachary S ZumstegBenjamin H LokAllen S HoEsther DrillZhigang ZhangNadeem RiazStephen L ShiaoJennifer MaSean M McBrideC Jillian TsaiShrujal S BaxiEric J ShermanNancy Y LeePublished in: Cancer (2016)
Toxicity from CCRT remains a challenge for older adults with OPSCC. Herein, the authors found no evidence that this toxicity was mitigated by treatment with cetuximab. Nevertheless, a subset of patients aged ≥70 years appear to tolerate cisplatin-based treatment with acceptable toxicity and excellent outcomes. Further identification of this patient subgroup is crucial to optimize therapy for older patients with OPSCC. Cancer 2017;123:1345-1353. © 2016 American Cancer Society.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- oxidative stress
- physical activity
- prognostic factors
- peritoneal dialysis
- radiation therapy
- squamous cell carcinoma
- middle aged
- early stage
- type diabetes
- clinical trial
- rectal cancer
- metabolic syndrome
- community dwelling
- case report
- combination therapy
- adipose tissue
- skeletal muscle
- replacement therapy
- open label
- phase iii